Navigation Links
New Details Presented at the World Parkinson Congress on Neurologix's Successful Phase 2 Trial of Gene Therapy for Parkinson's Disease
Date:10/1/2010

FORT LEE, N.J., Oct. 1 /PRNewswire-FirstCall/ -- Neurologix, Inc. (OTC Bulletin Board: NRGX), today announced that new details of the company's landmark, randomized, double-blind Phase 2 clinical trial of NLX-P101, its investigational gene therapy for advanced Parkinson's disease (PD), were presented during a symposium at the 2nd World Parkinson Congress in Glasgow, Scotland.  Co-principal investigator of the trial, Dr. Peter Lewitt, Director of the Parkinson's Disease and Movement Disorders program at Henry Ford Hospital, reported that, in addition to statistically significant improvements over the entire blinded study period in the off-medication motor scores between the treated and sham groups on the Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 (Motor section), 75 percent of patients in the treatment group were considered to have had a meaningful response to NLX-P101 (i.e., a five point or greater reduction in the off-medication UPDRS motor scores), which is comparable to the response rate of 71 percent in a recent study of Deep Brain Stimulation (Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs. best medical therapy for patients with advanced Parkinson's disease: a randomized controlled trial. JAMA 2009; 301:63-73).

Dr. Lewitt also emphasized that results showed a positive safety profile for NLX-P101, with no serious adverse events related to the gene therapy or surgical procedure reported.  Although details regarding the study methodology were also provided, such as catheter placement in the subthalamic nucleus (STN), specific quantitative outcomes were not discussed during the presentation, as these will be presented in a peer-reviewed publication, currently under review. 

Earlier this year, Neurologix disclosed top-line results for this Phase 2 trial, announcing that study participants who received NLX-P101 ex
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
2. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
3. Newly Published Article Details How PGS Techniques Directly Effect Successful Pregnancy Outcomes
4. Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast
5. Young Innovations, Inc. Provides Third Quarter Conference Call Details
6. Cord Blood America Details Las Vegas Laboratory Progress in Analyst Interview
7. Young Innovations, Inc. Provides 4th Quarter Conference Call Details
8. Kendle Announces Details Regarding Second Quarter 2010 Earnings Conference Call and Webcast
9. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 China Nepstar Chain Drugstore Ltd. (NYSE: ... chain in China based on the number ... 2014 Annual General Meeting of Shareholders (the "AGM") on October 22, ... at the meeting room of the Company at 6th Floor, Tower ... , Guangdong Province 518054, People,s ...
(Date:9/19/2014)... YORK , Sept. 19, 2014 Harwood ... against the board of directors of PDL BioPharma, Inc. ... concerning whether the board has breached its fiduciary duties ... On September 16, 2014, the Company disclosed: "On ... independent registered accounting firm, Ernst & Young LLP ("EY"), ...
(Date:9/19/2014)... 2014 "Copay coupons," a drug ... brand drugs among patients with prescription drug coverage, may now ... new report  from the Department of Health ... (OIG). Federal anti-kickback laws prohibit suppliers from offering side-payments ... by the federal government. The ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Schedules Annual General Meeting of Shareholders for October 22, 2014 2Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2PCMA: New OIG Report Cites Drug Manufacturer "Copay Coupon" Use in Medicare Part D 2
... Oct. 13, 2011 CVS Caremark (NYSE: CVS ... new partnership to identify, inspire and prepare young Latinos to ... of the prestigious HHF Youth Awards program. This fall and ... outstanding high school seniors of Latino descent for their academic ...
... Pharmaceutical Company (the "Company") (NYSE: KV.A/KV.B) appreciates that ... and Society for Maternal-Fetal Medicine (SMFM) have issued ... and the payer community have the facts regarding ... ACOG and SMFM statements regarding Makena were not ...
Cached Medicine Technology:CVS Caremark Partners With Hispanic Heritage Foundation to Identify and Inspire Future Latino Health Care Leaders 2CVS Caremark Partners With Hispanic Heritage Foundation to Identify and Inspire Future Latino Health Care Leaders 3K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 2K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 3K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 4K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 5K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 6K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 7K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 8
(Date:9/22/2014)... Metformin, a drug commonly used to treat diabetes, may ... (TSH) among patients with an underactive thyroid, a new ... levels may be associated with heart problems and broken ... this study. Among those in the study with ... low levels of thyroid-stimulating hormone per year compared with ...
(Date:9/22/2014)... Medical experts this past weekend gathered ... discuss brain-related diseases facing an aging population, including ... disorders. , Each of the 50 attendees ... memory care community or hospice office. Silverado, with ... hosts the annual event to facilitate the exchange ...
(Date:9/22/2014)... anxiety, excessive perspiration these symptoms are a few ... the body,s heart rate and plays a crucial role ... from Tel Aviv University points to an additional complication ... published in Mammalian Genome , was conducted by ... the Department of Human Molecular Genetics and Biochemistry at ...
(Date:9/22/2014)... leadership of Senators Sherrod Brown (D-Ohio) and Patty ... care services were lauded yesterday by the American ... representing internal medicine and related subspecialties. A ... introducing the Ensuring Access to Primary Care for ... extend current-law payment rates under Medicaid for certain ...
(Date:9/22/2014)... is one of 11 collaborating institutions that have been ... National Science Foundation for a project focused ... include plant symbionts, animal and human pathogens and decomposers ... used in numerous industrial processes and fermentation of foods, ... Symbiotic associations with zygomycetes may have facilitated the origin ...
Breaking Medicine News(10 mins):Health News:Diabetes Drug Metformin May Affect Thyroid in Some Patients 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 3Health News:Lack of thyroid hormone blocks hearing development 2Health News:Broad physician coalition urges Congress to extend Medicaid pay parity 2Health News:Project launched to study evolutionary history of fungi 2Health News:Project launched to study evolutionary history of fungi 3Health News:Project launched to study evolutionary history of fungi 4
... , REDWOOD CITY, Calif., June 2 Integromics, ... RealTime StatMiner(R) and Integromics Biomarker Discovery(TM) (IBD) for ... The resulting platform provides a uniform ... genomics data, and then identify relevant biological processes ...
... ... Isn,t Sexy, LLC announces an initiative to have all dentists screen their patients for both ... ... epidemic proportions in the United States, Snoring Isn,t Sexy, LLC announces an initiative to have ...
... ... HealthForumOnline (HFO), announces a new CE/CEU course entitled A Review ... and Coordination of Care of the Pain Patient to their extensive ... professionals, nurses and allied healthcare workers. While there is an ...
... (NYSE: SGP ) today announced that the ... the company,s Marketing Authorization Application (MAA) for SYCREST(R) (asenapine) ... episodes associated with bipolar I disorder. The application ... The MAA for SYCREST includes data from the asenapine ...
... , LOS ANGELES, June 1 Neurosurgeons, brain tumor researchers ... Department of Neurosurgery will present a one-day conference, ... to 4:30 p.m. The free conference is designed for brain ... the Medical Center,s Harvey Morse Auditorium, 8700 Beverly Blvd., Los ...
... , Support of local communities in the Silicon Valley , ... one of the nation,s first and leading providers of kidney ... announced their participation at the National Kidney Foundation (NKF) walk ... event will be held Saturday, June 6 at Cityview Plaza ...
Cached Medicine News:Health News:Ingenuity and Integromics Offer Integration for Comprehensive Genomics Analysis 2Health News:Founder of Snoring Isn't Sexy, LLC Urges All Dentists to Screen Their Patients for Snoring and Obstructive Sleep Apnea 2Health News:HealthForumOnline Offers New Online CE/CEU Course on Pain Screening Instruments for Medical and Mental Health Providers 2Health News:HealthForumOnline Offers New Online CE/CEU Course on Pain Screening Instruments for Medical and Mental Health Providers 3Health News:HealthForumOnline Offers New Online CE/CEU Course on Pain Screening Instruments for Medical and Mental Health Providers 4Health News:Schering-Plough Announces European Filing of SYCREST(R) (asenapine) for the Treatment of Schizophrenia and Bipolar I Disorder 2Health News:'Outsmarting Brain Tumors': Cedars-Sinai Researchers, Neurosurgeons and Other Experts Present Free Conference for Adult Brain Tumor Patients and Caregivers 2Health News:Satellite Healthcare Steps Out in San Jose 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: